Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), and is being investigated for the treatment of psoriasis.

There are currently no adequate or well-controlled studies of tofacitinib or any disease-modifying antirheumatic drug in pregnant women.

Pregnancy outcomes reported in the tofacitinib RA and psoriasis safety databases appear similar to those observed in the general population and in patients treated with biologic therapies for inflammatory diseases.